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ABSTRACT 
 
The prevalence of diabetes has nearly doubled since 1980, mounting from 4.7% to 8.5% in overall adult population. 
Thyroid disorder is another common endocrine disorder with prevalence of hypothyroidism as much as 4.6% and 
hyperthyroidism as much as 1.3% in population according to the National Health and Nutrition Examination Survey. 
These two most common endocrinopathies often co-exist and mutually influence each other. They have complex 
links of abnormal biochemical pathways, unregulated genetic expression of many genes and hormonal malfunctions. 
Thyroid hormones affects the regulation of carbohydrate metabolism, lipid metabolism and pancreatic function, and 
on the other hand, diabetes affects thyroid function tests to variable extents. In this review article we emphasized the 
epidemiology of diabetes and thyroid disorders, classification of thyroidism, and finally the impact of thyroidism to 
the various aspects of glucose and lipid metabolism in diabetics. 
 
Keywords: Hyperthyroidism, Hypothyroidism, Euthyroidism, Subclinical Hypothyroidism, Type 1 Diabetes 
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Introduction 
 
 
Diabetes mellitus (DM) and thyroid disorders (TD) are 
the two most common endocrine disorders, which often 
co-exist and mutually influence each other. A large 
number of studies have reported the association 
between DM and TD [1-5], and evidenced a range of 
complex links between biochemical, genetic and 
hormonal malfunction sex planning their patho- 
physiological association [5-7]. In 1927, Coller and 
Huggins proved the association of hyperthyroidism and 
deterioration of diabetes and found that the subtotal 
thyroidectomy improves glucose tolerance in patients 
with hyperthyroidism with coexisting diabetes [8]. The 
role of autoimmunity in the progression of TD has been 
observed among the people with type 1 diabetes 
mellitus (T1DM) and autoimmune thyroid disease [9].  
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A relationship between thyroid dysfunction and type 2 
diabetes mellitus (T2DM) has also been suggested, but 
the possible underlying mechanisms are complicated 
[10]. The most probable mechanism for development 
of T2DM in patients with thyroid dysfunction could be 
due to disturbed genetic expression of many genes 
along with physiological abnormalities leading to 
impaired glucose utilization by the muscles, increased 
hepatic glucose output, and increased glucose 
absorption from intestine [5]. These endocrinopathies 
impact each other in various ways. Thyroid hormones 
(TH) contribute to the regulation of carbohydrate 
metabolism and pancreatic function, and on the 
contrary, diabetes affects thyroid function tests to 
variable extents [4]. Altered plasma triiodothyronine 
(T3) and thyroxine (T4) levels have been observed in 
diabetic patients with poor glycemic control [11]. To 
understand the interaction of DM and TD, the 
association of Hashimoto’s thyroiditis 
(Hypothyroidism) and Graves’ disease (thyroid over-
activity) has been investigated in reference to DM. The 
importance of hyperinsulinemia/insulin resistance, in 
thyroid cell proliferation, which manifested as 
increased thyroid volume and nodule have been also 
observed [12-14].  
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Epidemiology 
An estimated 422 million adults were living with 
diabetes in 2014 worldwide, as compared to 108 
million in 1980. The over-all prevalence of diabetes 
has nearly doubled since 1980, escalating from 4.7% to 
8.5% in the adult population. In last decade, diabetes 
prevalence has increased more rapidly in low and 
middle-income countries than in high-income countries 
[15-16].  
As per 2017, National Diabetes Statistics Report, 30.3 
million Americans (9.4% of the population), had 
diabetes in 2015. Out of the 29.1 million, 23.1 million 
were diagnosed and 7.2 million were undiagnosed. The 
highest proportion of diabetes (diagnosed and 
undiagnosed), 25.2% (in total 12 million), still belongs 
to the Americans at par the age of 65. As per 
estimation in 2015, 84.1 million Americans (33.9%) 
adults with age 18 and older had prediabetes [17-18]. 
Thyroid disorder is another common endocrinopathy 
with variable prevalence [1]. Wang and Crapo in 1997 
mentioned that as many as 50% of people in the 
community have microscopic nodules, 3.5% have 
occult papillary carcinoma, 15% have palpable goiters, 
10% exhibit an abnormal thyroid-stimulating hormone 
(TSH) level and 5% of women have overt 
hypothyroidism or hyperthyroidism [19].  
Long back in 1977, Wickham survey reveals that the 
prevalence of thyroid dysfunction in male adults in 
England was 6.6% [20]. According to Colorado 
prevalence study, 9.5% of participants were found to 
have elevated TSH, while 2.2% had a low TSH [2]. 
According to the National Health and Nutrition 
Examination Survey (NHANES III Study), 
hypothyroidism and hyperthyroidism were reported in 
4.6% and 1.3% of the total participants, respectively 
[21].  
As per Framingham study, the observed prevalence of 
thyroid deficiency was 4.4%, evidenced by elevated 
serum TSH level in unselected population of elderly 
men and women (overt 60 years of age). The observed 
prevalence of thyroid deficiency in women was 5.9% 
more than men which was 2.3% [22]. As per NHANES 
III Study, the percentage of subjects with high serum 
thyroperoxidase antibodies (TPOAb) and thyroglobulin 
antibodies (TGAb) concentrations increases with age in 
both men and women [21]. The high concentrations of 
TPOAb and TGAb were more prevalent in women than 
in men and less predominant in blacks than in other 
ethnic groups [21]. As per Perros et al., the prevalence 
of thyroid dysfunction is increasing with age all over 
the world, and the frequency of prevalence was higher 
in women than men [23].The prevalence of palpable 
thyroid nodules in two non-biased population based 
studies, Framingham and Whickham, was 4.2 and 
3.2%, respectively [20, 23, 24]. In Germany, thyroid 
nodules or goiter were found in 33% of 96,278 
working adults aged 18-65 years screened by an 
ultrasound scan [25]. 
The overall prevalence of thyroid disease in diabetics 
was reported to be 13.4%, and was highest in T1DM 
females (31.4%) and lowest in T2DM males (6.9%) 
[23]. NHANES III study reported a higher prevalence 
of thyroid disease in diabetic subjects as compared to 
nondiabetics [21]. As per Greek study, the prevalence 
of thyroid dysfunction among T2DM was reported to 
be 12.3% with higher proportions in females than 
males [26]. A Saudi study of thyroid dysfunction 
among T2DM reported the prevalence of 16%, but the 
sample size was very limited [27]. A study from Jordan 
reported that thyroid dysfunction was present in 12.5% 
T2DM patients [28].  
A recent population-based prospective cohort study 
conducted by Chaker et al. on 8452 participants to 
access thyroid function, who were free of diabetes at 
baseline reported that associated risk of developing 
diabetes was 1.09 times higher for every doubling of 
TSH levels mIU/L. Within the normal range, the risk of 
diabetes was 1.16 times higher with higher TSH levels. 
In participants with prediabetes, the associated risk of 
developing diabetes was 1.13 times higher for every 
doubling of TSH levels. Considerably, T2DM patients 
were more prone to thyroid disorders [1]. 
The prevalence of subclinical hypothyroidism (SCH) 
was reported to be about 4 to 8.5%, and can reach up to 
20% in elderly women (over 60 years of age). In 
general population, the prevalence of SCH was 
reported to be approximately 2% [31] and in T2DM 
population about 10.2% [29-31]. As per NHANES III 
study, the prevalence of SCH in white, non-Hispanic 
women was reported to be 5.8% and 3.4% in men; 
while among blacks, non-Hispanic women 1.2% and 
1.8% in men; further more in Mexican-American 
women and men it was 5.3% and 2.4% 
respectively [21]. Han et al. observed that the T2DM 
was associated with a 1.93 fold increase in risk of 
SCH. They observed that gender difference, old age, 
and an apparent geographic disparity were related to 
the prevalence of SCH in T2DM [31]. Among T2DM 
population, the women had 1.7 times higher prevalence 
of SCH than men and elderly T2DM (over 60 years of 
age) and were reported to experience SCH associated 
risks more frequently [31].  
Thyroid hormone and Classification of Thyroid 
Disorders 
Thyroglobulin and iodine are required for synthesis of 
monoiodotyrosine and diiodotyrosine, which are 
precursors for triiodothyronine (T3) and thyroxine 
(T4). The T4 is synthesized only in the thyroid, which 
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is inversely controlled by pituitary gland hormone 
TSH, while 80% of T3 can be produced by 
deiodination of T4 in specific tissues. The T3 have 10-
times higher affinity than T4 on nuclear thyroid 
receptor proteins and further these receptor proteins 
activate the transcription and translation of growth 
hormone (GH), thyrotropin-releasing hormone (TRH), 
malic enzyme, myosin, calcium channel and so on [32-
33]. 
The functional behavior of the thyroid hormones are 
fundamental in majority of the thyroid diseases and 
clinical states; reflecting normal, excessive or defective 
levels of thyroid hormones. Altered hormone levels are 
the basis of classification. Thyroid function tests 
(TFTs) are used in diagnosing hypothyroidism or 
hyperthyroidism in symptomatic patients. However, the 
interpretation of TFTs needs to be put in perspective as 
TFTs may reflect on non-thyroid pathology, such as 
hypothalamic or pituitary disease [32-34].  
Euthyroidism means normal production of thyroid 
hormone (TH) by the thyroid, normal circulating and 
intracellular level of TH. Euthyroidism have normal 
TSH and free T4 (FT4) or TBG [33-35]. 
Hyperthyroidism means clinical symptomatology due 
to excessive circulating and intracellular TH. If the TH 
are produced by the thyroid in excess due to thyroid 
gland hyper-function, it is known as hyperthyroidism. 
If the excess level of TH is due to excess secretion 
rather than production without thyroid gland hyper-
function, the condition is called thyrotoxicosis. Patients 
with hyperthyroidism have low or undetectable TSH 
and increased levels of FT4 or decreased TBG [33-35]. 
The term subclinical hyperthyroidism (SCH) describes 
a condition with low TSH level and normal serum 
concentration of FT4 or TBG. SCH has the same 
causes as overt hyperthyroidism [33-35]. 
Hypothyroidism is almost always due to the lack of TH 
production and inadequate replacement therapy. 
Patients with primary hypothyroidism have increased 
TSH concentration (as a result of the body’s attempt to 
produce more TH), and low serum concentration of 
FT4 or increased TBG [33-35]. 
Effect on Glucose Metabolism 
Chaker et al. has recently reported that hypothyroidism 
is associated with an increased risk of diabetes. Further 
they also described that pre-diabetics with 
hypothyroidism are at greater risk for progression to 
diabetes than pre-diabetics with euthyroid or 
hyperthyroid state [1]. Gronich et al. and Thvilum et 
al. also reported increased risk of diabetes in 
hypothyroid individuals [36-37]. While the Danish 
study by Brandt et al. reported opposite results, that an 
increased risk of diabetes in hyperthyroid individuals 
[38]. However, there are several factors that could 
explain these differences, like variance in the mean 
age, possible iodine status of the studied population 
and misclassification as Brandt et al. have not included 
laboratory measurements of thyroid function [1].  
The relationship between hypothyroidism and the risk 
of diabetes can be explained by alteration of many 
pathways.TH is a major regulator of metabolism and 
energy expenditure. TH is directly involved in the 
control of insulin secretion and influences plasma 
glucose levels, insulin sensitivity, and carbohydrate 
metabolism by interacting to the liver, white adipose 
tissue, skeletal muscle, and pancreas [4, 39-40]. TH has 
been observed to preserve beta-cell viability and 
proliferation as well [41-42]. 
Glucose metabolism is affected via several 
mechanisms in hypothyroidism. It is observed that 
there is a reduced rate of liver glucose production via 
gluconeogenesis and glycogenolysis in patients with 
hypothyroidism [42]. Leong et al. reported that 
repeated hypoglycemic episodes are the presenting 
signs for the development of hypothyroidism in T1DM 
and replacement with TH reduces these episodes [43]. 
The hypothyroidism down-regulates the plasma 
membrane glucose transporters and premature insulin 
degradation [44-45]. The hypothyroidism and SCH 
have been recognized as insulin resistant states [46-47]. 
Studies have shown that this is due to impaired insulin 
stimulated glucose utilization in peripheral tissues [46-
47]. Treatment of hypothyroidism has been revealed to 
restore insulin sensitivity and the secretion of 
glucoregulatory hormones [6, 48]. The 
hyperthyroidism is associated with insulin resistance 
but this high and high-normal thyroid functions are 
protective to progression of diabetes as the 
hyperthyroidism causes increased insulin secretion [41, 
49-51]. In vitro studies suggest that T3 and Thyroid 
Receptor alfa (TRα) promote proliferation of 
pancreatic islet cell. T3 also stimulates the islet 
transcription factor Mafa, which contributes to the 
transition of islets to glucose-responsive insulin-
secreting cells, which further improves the insulin 
secretion in presence of higher free T3 in prediabetics 
[50-51]. Studies suggest that during hyperthyroidism 
the release of insulin precursors increases but they are 
inactive form and due to that insulin degradation rate 
increases and the half-life of insulin is reduced [52-53]. 
The above mentioned hypothesis was supported by 
Bech et al., as they observed the increased proinsulin 
levels in response to a meal in untreated Graves’ 
disease [54]. Other studies reported that untreated 
hyperthyroidism were associated with a reduced C-
peptide to proinsulin ratio and suggested an underlying 
defect in proinsulin processing [55]. It was also 
observed that hyperthyroidism and high-fat diet result 
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in significant impairment of islet function [56]. 
Fazacappa et al. suggested that physiological T3 
concentration prevents islet deterioration and maintains 
islet structure, size, and consistency [57]. Hence, it can 
be deduced that if the T3 concentration is within 
normal range it helps to maintain the islet structure, 
proliferation, and secretion of active insulin, while 
augmented T3 level overwhelms the islet cells, which 
causes improper proliferation and secretion of inactive 
insulin. 
Hyperthyroidism causes increased liver 
gluconeogenesis and peripheral insulin resistance and 
is associated with glucose intolerance [58-59]. The 
non-oxidative glucose disposal enhanced during 
hyperthyroidism results in an over-production of 
lactate that further promotes hepatic gluconeogenesis 
[60]. It has been observed that elevated T3 stimulates 
gluconeogenesis, as treatment of T3 on hepatocytes up-
regulates the gene expression of gluconeogenesis 
enzyme phosphoenolpyruvate carboxykinase (PEPCK) 
via upregulation of TRβ and CCAAT enhancer binding 
protein [61-62]. These upregulations were resistant to 
insulin suppression of hepatic glucose production 
compared with euthyroid [62-63]. Augmented T4 
increases the transport of alanine to liver and increases 
gluconeogenesis [64]. TH also induces the synthesis of 
hepatocyte glucose transporter-2 (GLUT-2), which 
consequently increases hepatic glucose output and 
causes abnormal glucose metabolism [65-66]. 
The hepatic insulin resistance is mediated by 
sympathetic stimulation. The administration of T3 to 
the hypothalamic paraventricular nucleus increases 
glucose production via sympathetic input to the liver 
through interaction with the sympathetic nervous 
system, showing that the T3 effect was central [67]. 
Further, hyperthyroidism associated with release of 
growth hormone, glucagon, and catecholamine, which 
also contributes to the impaired glucose tolerance [68-
69]. Another mechanism explaining the relationship 
between hyperthyroidism and hyperglycemia is 
increase in intestinal glucose absorption mediated by 
the excess TH [70-71]. 
Lipid Metabolism 
TH affect lipoprotein metabolism. It has been observed 
that even in euthyroid state, the increased TSH level 
within the normal range causes an increase in total 
cholesterol (TC), low-density lipoprotein cholesterol 
(LDL-C), and triglycerides (TGs) and a decrease in 
high-density lipoprotein cholesterol (HDL-C) [72-73]. 
TH up-regulates the cholesterol synthesizing 3-
hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) 
reductase and LDL receptor gene expression through 
sterol regulatory element-binding protein-2 (SREBP-2) 
and via direct binding of T3 to specific thyroid 
response elements (TREs) [74]. TH can also affect the 
HDL-C metabolism by increasing cholesteryl ester 
transfer protein (CETP) activity, which exchanges 
cholesteryl esters from HDL2 to very low density 
lipoproteins (VLDL) and TGs from VLDL to HDL2 
[75]. TH stimulates the lipoprotein lipase (LPL) via 
reducing the expression of angioprotein-like 3 
(ANGPTL3), a potent LPL inhibitor. Over expression 
of ANGPTL3 significantly enhances TC, non-esterified 
fatty acid and TGs [76], while TH treatment reduced 
ANGPTL3 mRNA expression through TRβ and 
improves the condition [77-78].  
TH up-regulates the gene expression of APOA5 
(apolipoprotein A-V) and further the ApoA5 protein, 
which have been associated with decreased levels of 
TGs [78-79]. Patients with mutation of APOA5 
manifest markedly reduced plasma LPL activity and 
hypertriglyceridemia [80]. Moreover, ApoA5 causes a 
greater clearance of lipoprotein remnants by increased 
hepatic uptake due to enhanced LDL receptor activity 
[78-79]. 
In hypothyroidism, the decreased thyroid function is 
accompanied by reduced activity of HMG-CoA 
reductase and increased serum TC, LDL-C, remnants 
of VLDL, Chylomicron (CM), oxi-LDL, ApoB [81-
82], while TG, HDL-C, and VLDL are normal or 
slightly increased [83-85]. In hypothyroidism, TH 
decreases the LDL receptor expression and cholesterol 
absorption overshadow the effects of decreased hepatic 
cholesterol biosynthesis, leading to high serum levels 
of LDL-C, IDL-C, and TC levels [86]. 
Patients with hypothyroidism usually have higher 
LDL-C, leading to increased oxidized (oxi)-LDL. Oxi-
LDLs are taken up by macrophages in the arterial walls 
to produce foam cells, and become a risk factor for 
atherosclerosis. The high levels of oxi-LDL are 
reversible with levothyroxine (L-T4) treatment [87]. 
Moreover, a decrease in LPL activity due to over 
expression of LPL inhibitor ANGPTL3 had been 
observed in hypothyroidism, which decreases the 
clearance of TG-rich lipoproteins and presented with 
elevated levels of VLDL and occasionally fasting 
chylomicronemia [88-89]. Hypothyroid patients were 
also observed to exhibit elevated levels of HDL-C, 
especially HDL2 due to reduced hepatic lipase (HL) 
activity which reduces the HDL2 catabolism to HDL3 
[84, 90]. Hypothyroidism also inhibits the transcription 
of the apolipoprotein A1 (APOA1) gene, but the 
decreased activity of HL results in slower clearance of 
Apo A-1 protein, thus leading to increased Apo-A1 
levels. Human studies show that Apo A-1 levels are 
decreased in hyperthyroidism and increased in 
hypothyroidism, whereas Apo A-2 levels are not 
influenced by either hyperthyroidism or 
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hypothyroidism [90-91]. Further, decreased activity of 
the CETP results in reduced transfer of cholesteryl 
esters from HDL to VLDL, thus increasing HDL-C 
levels [92]. Studies showed that lipoprotein (a) [Lp(a)] 
levels are increased in patients with hypothyroidism 
and decrease after levothyroxine (L-T4) treatment. The 
mechanism may be related to the decreased clearance 
of Lp(a) mediated by the LDL-R degradation pathway 
[23]. ApoB levels are higher in both overt and SCH 
and have been shown to decrease after L-T4 treatment 
[93-94]. The lipid abnormalities in overt 
hypothyroidism are reversible with L-T4 therapy 
unless the patient has underlying hyperlipidemia [95]. 
SCH is associated with increased levels of TC and 
LDL-C [96-99]. In addition, some studies have shown 
that SCH-induced dyslipidemia may also be 
accompanied by increased TGs [100-101] and 
decreased HDL-C levels [102]. Moreover, subjects 
with high normal TSH levels (2-4 mIU/L), but with 
positive TPOAb and TgAb may also exhibit elevated 
cholesterol levels [103]. Most studies have shown 
increased Lp(a) levels related to SCH [104-105]. An 
interesting study evaluated serum Lp(a) levels along 
with corresponding APOA phenotypes, which are 
known to influence Lp(a) levels, in SCH patients [106]. 
There is some controversy regarding the presence or 
the severity of SCH-induced dyslipidemia. Indeed, 
there have been studies indicating no significant 
difference in lipid profile between SCH patients and 
controls [89,107]. In hyperthyroidism, serum levels of 
total cholesterol, LDL-C and HDL-C are decreased and 
oxi-LDL levels are increased [108]. In hyperthyroid 
condition, TGs level showed either no change or 
decrease [90, 109], partly, due to T3 down regulation 
of ANGPTL3 and stimulates PLP, leading to 
hydrolysis of TGs. Then, T3-mediated LDLR 
stimulation dramatically increases clearing capacity for 
LDL-C [76]. The reason for the mild hyper-
triglyceridemia is unclear. Lipolysis is augmented in 
hyperthyroidism with elevation of free fatty acids 
(FFA) in plasma, but hepatic lipogenesis is also 
augmented due to increased FFA flux from adipose 
tissue to the liver [82]. This increased lipolysis 
resulting in an increase in FFA that stimulates hepatic 
gluconeogenesis. The increased release of FFA could 
partially be explained by an enhanced catecholamine 
stimulated lipolysis induced by the excess TH [110]. 
 
Conclusion 
 
Thyroid dysfunction and diabetes are closely 
associated with each other and characterized by a 
complex interaction. Insulin resistance states may 
increase thyroid gland nodularity. Uncontrolled 
hyperthyroidism in diabetes may trigger hyperglycemic 
emergencies while recurrent hypoglycemic episodes 
may exist in diabetic patients with hypothyroidism thus 
complicating diabetes management. Low and low-
normal thyroid function also related to an increased 
risk of diabetes.In individuals with prediabetes and low 
and low-normal thyroid function, the risk of 
progression to diabetes more prominent. SCH is more 
prevalent in T2DM patients and that SCH may confer 
greater risk of diabetic complications. Furthermore, 
thyroid hormones also alter carbohydrate and lipid 
metabolism. Biochemical screening for thyroid 
dysfunction is critical in all dyslipidemic patients, as 
well as all patients with unexpected improvement or 
worsening of their lipid profile. Subsequent studies 
could address possible screening and treatment 
modalities for both diabetes and thyroid dysfunction. It 
is therefore important to diagnose thyroid dysfunction 
in diabetic patients and this practice should be 
inculcated in diabetic care. So, it’s important for 
clinicians to identify the diabetic patients who are at 
risk for developing thyroid disorder and control the 
thyroid anomalies to reduce the chances of further 
complications. 
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